BTIG Boosts PT on Progenics Pharma (PGNX) to $11 Amid NT Pipeline Visibility

November 30, 2016 12:18 PM EST
Get Alerts PGNX Hot Sheet
Price: $8.92 +0.68%

Rating Summary:
    5 Buy, 2 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 17 | Down: 26 | New: 28
Trade PGNX Now!
Join SI Premium – FREE

Get access to the best calls on Wall Street with StreetInsider.com's Ratings Insider Elite. Get your Free Trial here.

BTIG lifts its price target on Progenics Pharmaceuticals (Nasdaq: PGNX) from $9 to $11, noting potential near-term pipeline visibility.

The firm commented today, Earlier this month, we visited the Co. at their new offices in NYC, and went over several of the pipeline product opportunities, including Azedra. In 1Q17, we expect top-line results from its Phase 2b trial with Azedra (radiotherapeutic for the treatment of pheochromocytoma – a rare form of cancer in the adrenal glands). We see Azedra as a somewhat de-risked asset for an orphan disease indication where there are currently no approved treatments. Progenics plans to submit an NDA for Azedra in 1H17, if results are positive. The FDA has assigned Fast Track Status to Azedra, which suggests an expedited review is possible.

BTIG rates Progenics at Buy.

For an analyst ratings summary and ratings history on Progenics Pharmaceuticals click here. For more ratings news on Progenics Pharmaceuticals click here.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Analyst Comments, Analyst PT Change

Related Entities

BTIG

Add Your Comment